The SCG5 antibody targets Secretogranin V (SCG5), a member of the granin family of acidic secretory glycoproteins, which includes chromogranins and secretogranins. SCG5 is primarily expressed in neuroendocrine cells, neurons, and certain endocrine tissues, where it is stored in secretory granules. It plays roles in hormone/peptide biosynthesis, granule formation, and regulated secretion. SCG5 is proteolytically processed to generate bioactive peptides like secretoneurin, implicated in angiogenesis, neuroprotection, and immune modulation.
SCG5 has gained attention in biomedical research due to its association with neuroendocrine tumors (NETs), neurodegenerative diseases, and metabolic disorders. Overexpression of SCG5 has been reported in pancreatic NETs, pheochromocytomas, and pituitary adenomas, suggesting its potential as a diagnostic or prognostic biomarker. In Alzheimer’s disease, altered SCG5 expression may correlate with synaptic dysfunction.
Antibodies against SCG5 are essential tools for detecting its expression in tissues (e.g., immunohistochemistry) or biological fluids (e.g., ELISA). They help elucidate its physiological roles and pathological relevance. Commercial SCG5 antibodies are typically raised in rabbits or mice using peptide antigens from conserved regions. Validation includes Western blotting to confirm specificity for the ~75-80 kDa protein and cross-reactivity assessments. Challenges include distinguishing SCG5 from homologous granins and detecting processed fragments. Ongoing research explores SCG5's therapeutic potential, driving demand for reliable antibodies.